Talzenna (Talazoparib)

Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. 

Recommended Dosage: The recommended dose of Talzenna Capsule is 1 mg taken orally once daily, with or without food. When the dose reduction is required, 0.25 mg capsules can also be used. Patients should be treated until the disease is progressive or unacceptable toxicity occurs.

 The hard capsules of Talzenna should be swallowed whole and must not be opened or dissolved. If a patient misses or vomits a dose, an additional dose of Talzenna should not be taken. Take the very next prescribed dose at the usual time.

• Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) may be reported in those who received Talzenna 0.25mg capsules. Do not start treatment until patients have adequately recovered from hematological toxicity due to previous chemotherapy.
• CBC needs to be monitored for cytopenia at baseline and then monthly basis. For prolonged hematological toxicities, interrupt treatment and assess blood counts weekly until recovery. In case the levels have not recovered after four weeks, refer the patient to a hematologist for further evaluations, including bone marrow analysis and blood sample for cytogenetics. In case MDS/AML is suspected, discontinue treatment.
• Myelosuppression consisting of leukopenia/neutropenia, anemia, or thrombocytopenia, may occur in those treated with Talzenna 0.25mg or with any other dosage strength. Monitor complete blood count (CBC) for cytopenia at baseline and monthly thereafter.
• Depending on its mechanism of action and data, Talazoparib treatment can cause fetal harm if used by pregnant women. Those with reproductive age should use apt contraception during therapy and for at least seven months following the final dose of Talazoparib. 
• Due to the risk for serious side effects in a breastfed child from Talazoparib 1mg Capsule, lactating women should not breastfeed throughout the treatment and for at least 40 days after the last dose. A pregnancy test is required for females of reproductive age prior to initiating Talazoparib treatment. 

What documents are required to import TALZENNA® to India?

TALZENNA® (Talazoparib) capsules can be imported by patients or government hospitals on behalf of patients.

The following documentation is needed to import the medicinal product:

• Valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s Proof of Identity (issued by the Government of India).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from a doctor.
• Import permit if applicable.

Is TALZENNA® available in India?

TALZENNA® (Talazoparib Capsule) is a prescription pharmaceutical drug that legally requires a medical prescription to be dispensed. Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability of Talzenna 0.25mg in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Pune, Bangalore, Chennai, etc.).
• Medicine Price.
• Finding the most reliable and genuine source from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

TALZENNA® can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of TALZENNA® (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Talzenna® price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source TALZENNA® (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Talzenna®?

Talazoparib is the Generic Name for the trade name drug Talzenna®.

What is the Manufacturer’s Name of Talzenna®?

Talzenna® is manufactured by Pfizer Inc.

Is Talzenna® approved by the FDA?

Yes, Talzenna® is approved by the FDA. Date of first/initial approval: October 16, 2018.

What is the dosage and form of Talzenna® supplied?

Talzenna® is supplied as Capsules: 0.25 mg, 1 mg for oral administration.

What are the most common side effects of Talzenna®?

The most common side effects of Talzenna® include: nausea, fatigue, anemia, neutropenia, thrombocytopenia, headache, vomiting, alopecia, decreased appetite, and diarrhea.

How much does Talzenna® cost in India?

Talzenna® cost in India is very reasonable. To procure this Breast Cancer medication authentically, you can dial our TOLL-FREE: 1800-889-1064, or call/WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Talzenna®?

Store the capsules at a temperature of 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Is it safe to buy Talzenna® online from India?

Yes, you can buy Talzenna® 0.25 mg and 1 mg online from India authentically from Urgent Meds if Talzenna® is not available or has not been approved in your home country.